Hodgkin Disease

Please read these Terms of Use and Privacy Statement (collectively, the "Terms") carefully before using any of the box above indicates that you accept these Terms.

Hodgkin Disease
x

Are you interested in possibly participating in a clinical trial for Warm Autoimmune Hemolytic Anemia?

Read More

Following specialists treat  Hodgkin Disease. Help us improve our data based on your experience.

Based on your feedback, we will add the specialty within 1 month


Submit

100%

100%

100%

0%20%40%60%80%

Specialty scores for Hodgkin Disease

Overview

Source: In partnership with Genetic and Rare Diseases Information Center, funded by the National Center for Advancing Translational Sciences, and the National Human Genome Research Institute https://rarediseases.info.nih.gov/gard.

Terms of Use

Hodgkin lymphoma

Presentation(s)

Abnormality of immune system physiology

Lymphadenopathy

Lymphoma

Abnormality of temperature regulation

Anorexia

Chest pain

Hyperhidrosis

Pruritus

Weight loss

Bone marrow hypocellularity

Bone pain

Hemoptysis

Hepatomegaly

Incoordination

Migraine

Peripheral neuropathy

Respiratory insufficiency

Splenomegaly

Autosomal recessive inheritance

Hodgkin lymphoma

Impaired lymphocyte transformation with phytohemagglutinin

Polyclonal elevation of IgM

medical Products

Brentuximub Vedotin

Trade Name: Adcetris

Indication: The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

nivolumab

Trade Name: Opdivo

Indication: The treatment of Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.

FDA Approved Medicines

  • FDA approved brentuximab vedotin, sold as Adcetris, manufactured by Seattle Genetics for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma ( Hodgkin Disease | Anaplastic Large Cell Lymphoma ) in year 2011.